Background-The GATA4 gene is critical to regulating myocardial differentiation and function. Haploinsufficiency of GATA4 is strongly associated with congenital heart defects (CHD). However, it is inconclusive whether duplicated GATA4 causes CHD. Methods and Results-We evaluated 1645 consecutive pediatric patients with various developmental disorders by highresolution microarray-based comparative genomic hybridization and found 8 probands and 2 relatives with pathogenic genomic imbalances containing GATA4. Four probands contain an Ϸ4.0-Mb interstitial duplication of 8p23.1 flanked by the 2 olfactory receptor gene clusters REPD and REPP, representing 0.24% (4/1645) of the patients analyzed. None of the 4 patients has CHD or any other heart diseases and 1 mother who transmitted the duplication to her child has a history of aortic stenosis. Two patients who carry multiple genomic abnormalities, including a duplication containing GATA4, have complex CHD. Only 1 of the 3 individuals carrying genomic deletion containing GATA4 has atrial septal and ventricular septal defects. Conclusions-Cardiac defects are infrequent findings in individuals with 8p23.1 genomic duplications containing GATA4.
T he GATA4 gene is located on the short arm of human chromosome 8 (8p23.1:11,599,126 -11,654,918) containing 7 exons. It encodes member 4 of the GATA-binding proteins, a group of structurally related transcription factors controlling gene expression and differentiation in a variety of cell types. 1 This gene is expressed in yolk sac endoderm during fetal development and in adult vertebrate heart, gut epithelium, and gonads. By regulating genes critical for myocardial differentiation and function, including troponin C (TNNC1 and TNNC2), ␣-myosin heavy chain 6 of cardiac muscle, and brain natriuretic peptide, GATA4 plays an important role in heart formation. 1, 2 Genetic defects (eg, missense mutation, nonsense mutation, deletion) leading to the haploinsufficiency of GATA4 are strongly associated with conotruncal and septal heart defects. [3] [4] [5] [6] [7] [8] [9] Clinical Perspective on p 625
With application of molecular cytogenetic techniques, such as florescence in situ hybridization (FISH) and microarraybased comparative genomic hybridization (aCGH), an Ϸ4.0-Mb genomic duplication of 8p23.1 containing GATA4 has been reported in Ͼ10 individuals with a diversity of clinical findings, such as developmental delay, learning disability, mild dysmorphism, and heart defects. 10 -15 However, there are debates about whether the duplicated GATA4 underlies the congenital genetic defects in these patients. 13, 16 In the present study, we report on 8 probands and 2 relatives carrying genomic imbalances containing GATA4 identified by genomewide high-resolution aCGH as well as other genetic tools. The possible pathogenic role of GATA4 in the generation of the congenital heart defects was assessed and relevant literature reviewed.
Methods

Specimens
From April 2008 to July 2010, we evaluated 1645 consecutive pediatric patients by aCGH technique in our laboratory. Referral justification included Ն1 of the following clinical findings: developmental delay, autism, dysmorphic features, seizures, or multiple congenital anomalies. Eight patients were found to carry genomic imbalances containing GATA4 of whom 4 were briefly described in our previous study that explored the genomic mechanisms underlying the formation of chromosomal abnormalities on the short arm of chromosome 8. 14 The present study protocol was approved by the Institutional Review Board of Children's Mercy Hospitals and Clinics.
aCGH Testing, Result Verification, and Parental Follow-up
The aCGH tests were performed using the Agilent Human Genome Microarray Kit 244K or 4ϫ180K platforms following the protocols described (Agilent Technologies; Santa Clara, CA). 17 Chromosome karyotyping (G banding) using a standard protocol was performed for all cases. FISH was carried out for cases 5, 6 , and 8 as recommended by the manufacturers (Vysis Inc; Downers, IL). The genomic imbalances containing GATA4 identified by aCGH also were verified by quantitative real-time polymerase chain reaction using test primers targeted to GATA4 as reported previously (onlineonly Data Supplement Table I ). 18 The quantitative real-time polymerase chain reaction method also was carried out for parental follow-up studies.
Results
Genomic Imbalances Containing GATA4
We limited our description to the patients with genomic imbalances containing GATA4. Of the 1645 pediatric patients, GATA4 was duplicated in 6 (patients 1-6) and deleted in 2 (patients 7-8) ( Table 1 The genomic imbalances containing GATA4 in these 8 patients were verified by quantitative real-time polymerase chain reaction methods (data not shown). Twelve parental samples were available for determination of the inheritance pattern of the genomic abnormalities in their respective children (Table 1) . Although the genomic abnormalities in patients 2, 4, 5, and 6 were found to occur de novo, the abnormalities in patients 3 and 7 were inherited from 1 of the parents. The parents for patients 1 and 8 were not available for testing.
Clinical Features in the 12 Patients With Genomic Abnormalities Containing GATA4
The major clinical findings in these patients are summarized in Table 2 . Patients 1 to 4 contain an Ϸ4.0-Mb interstitial duplication of 8p23.1 flanked by the REPD and REPP clusters. Recurrent features in the 4 patients include developmental delay (4/4), dysmorphic features (3/4), and neurodevelopmental problems (2/4). Some isolated findings also were observed, such as, abnormal movements, familial congenital hypothyroidism, portal vein thrombosis, and hypospadias. None of the 4 patients has CHD or any other heart diseases. Patient 3 inherited the 8p23.1 duplication from her mother, who has a history of learning disability and aortic stenosis.
In addition to the 8p23.1 duplication, patients 5 and 6 have other genomic abnormalities. Clinically, both patients have complex CHD, with bicuspid aortic valve with aortic dilation, patent ductus arteriosus, and anomalous superior left pulmonary venous return in patient 5 and tetralogy of Fallot, patent ductus arteriosus, and complete atrioventricular canal defect in patient 6. Patient 5 has severe global developmental delay, mood disorder, and behavioral abnormality, whereas patient 6 has had growth delay both prenatally and postnatally.
Different from patients 1 to 6 who carry 8p23.1 duplication, patients 7 and 8 carry 8p23.1 deletion. Clinically, both patients have developmental delays and behavioral problems. Patient 7 has atrial septal defect (ASD) and ventricular septal defect (VSD), whereas patient 8 has a normal heart. Although the 8p23.1 deletion in patient 7 was inherited from her father, the father is healthy without detectable problems in his heart and other organs.
Discussion
It is controversial whether a duplicated GATA4 may cause cardiac defects. 13 , 16 Barber et al 10, 13 carried out genotype-phenotype correlation in both prenatal and postnatal cases with 8p23.1 duplication containing GATA4 and Ͼ50 other genes. They summarized the clinical data from 11 patients with 8p23.1 duplication in 7 families. CHD was the most common single feature, having been found in 6 of 11 individuals. They proposed that duplication of GATA4 can give rise to a variety of conotruncal or septal heart defects with variable penetrance and expressivity. Basinko et al 15 identified a partial trisomy containing Ϸ60 genes, including GATA4, in a patient with CHD, delayed puberty, and learning disabilities. They supported the proposal that the 8p23.1 duplication is associated with ASD, probably because of GATA4 duplication. However, opposite opinions exist. Joziasse et al 16 identified a 132.9-kb duplication containing only 1 gene, GATA4, in a boy with developmental delay; dysmorphic features; and multiple congenital anomalies, including CHD. This duplication was inherited from his healthy mother. Three additional family members carrying the GATA4 duplication were identified, and none of them had cardiac symptoms or any observable congenital cardiac defect. Joziasse et al concluded that GATA4 duplication is not sufficient to cause CHD. They further proposed that the CHD in the proband might be caused by a different gene, FAM123B, which also was duplicated in his genome, rather than by the GATA4 duplication. Additional evidence that does not support the involvement of duplicated GATA4 in CHD came from a report by Zogopoulos et al 19 that the Ϸ4.0-Mb duplications containing GATA4 occur in the general population at a frequency of 0.6% (7/1190).
In the current study, none of the 4 patients (patients 1-4) who carry an Ϸ4.0-Mb interstitial duplication of 8p23.1 containing GATA4 has CHD or any other heart diseases. However, the mother of patient 3 who carries the duplication has a history of aortic stenosis. Based on these data, we believe that duplicated GATA4 is less likely to be sufficient to cause CHD. Interestingly, both patients 5 and 6 who carry multiple genomic abnormalities have complex CHD. A possible explanation is that the CHD in these 2 patients was caused by other genomic abnormalities rather by the duplicated GATA4. An alternative explanation is that there are genes in other abnormal regions in concert with the duplicated GATA4 leading to CHD development, which is consistent with a recently described 2-hit model in which 2 insults are necessary during development to result in a visible or more severe clinical manifestation as pediatric disease. 20 Different from the CHD observed in only 1 of the 5 individuals (patients 1-4 and the mother of patient 3) who carry the Ϸ4.0-Mb 8p23.1 duplication containing GATA4, developmental delay was present in each of the 4 probands, ranging from mild to severe, and learning disability was present in the mother of patient 3. Dysmorphic features also were found in 3 of the 4 probands. Both developmental delay and dysmorphic features were observed in previously reported patients who carried genomic duplication containing GATA4. 10, 13, 15 However, some isolated findings in the 4 probands, such as portal vein thrombosis and hypospadias, were not previously observed. The finding of 4 probands with 8p23.1 duplication, or a 0.24% detection rate, indicates that the 8p23.1 duplication may be more common than the estimated prevalence of 1 in 64 000 by Barber et al. 10, 13 However, it remains unknown why the frequency of 0.6% (7/1190) of the Ϸ4.0-Mb duplications containing GATA4 occurred in the general population reported by Zogopoulos et al, 19 although they were not examined with regard to neurological and psychiatric phenotypes. It is noteworthy that no examples of the Ϸ4.0-Mb 8p23.1 duplication containing GATA4 have been observed in the 1287 healthy individuals 21 or documented among the 66 741 copy number variants currently in the Database of Genome Variants (http://projects.tcag.ca/variation). Patient 7 inherited an Ϸ4.0-Mb 8p23.1 deletion from her father, which is reciprocal to the 8p23.1 duplication in patients 1 to 4 ( Figure, Table 1 ). She has ASD and VSD consistent with the clinical findings in previously reported patients carrying the Ϸ4.0-Mb 8p23.1 deletion with a spectrum of cardiac defects that included ASD, VSD, atrioventricular septal defect, pulmonary valve stenosis, tetralogy of Fallot, and combinations of these defects. 22 Patient 7 inherited this deletion from her father, who has no observable cardiac defect, reflecting incomplete penetrance of haploinsufficient GATA4 causing CHD. This idea is supported by the observation in patient 8, who is absent of CHD but carries a 15.66-Mb 8p terminal deletion containing GATA4.
In summary, we identified 7 individuals (patients 1-6 and the mother of patient 3) with genomic duplications containing GATA4. Only 1 of the 5 individuals who carry an Ϸ4.0-Mb interstitial duplication of 8p23.1 has a history of aortic stenosis, indicating that cardiac defects are infrequent findings in individuals with this duplication. A 0.24% detection rate of 8p23.1 duplication in this study indicates that the previously calculated prevalence of this duplication was underestimated. Both patients who carried multiple genomic abnormalities, including a duplication containing GATA4, have complex CHD consistent with the 2-hit model emphasizing accumulative effects of Ͼ1 insult to the genome, leading to a visible or more severe clinical manifestation. Only 1 of the 3 individuals carrying genomic deletion containing GATA4 has ASD and VSD, reflecting incomplete penetrance of haploinsufficient GATA4 causing CHD.
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